MLYS today
$15.50-$0.66 (-4.08%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourExpanding
15 minLeaning Bullish
5 minDescending Triangle
Daily trend turns up above $17.66
Key levels
Resistance$20.18
Resistance$17.66
Support$15.33
Support$12.59
Latest news & SEC filings
ProductMineralys Therapeutics reports late-breaking lorundrostat data from Transform-HTN extension
AnalystUBS trims its valuation view for Mineralys Therapeutics to $19
EarningsMineralys Therapeutics Posts Q3 2026 Financial Results
All MLYS news →About Mineralys Therapeutics
Mineralys Therapeutics is a biopharmaceutical company developing medicines for diseases caused by dysregulated aldosterone. Its lead product candidate, lorundrostat, is an oral aldosterone synthase inhibitor being developed for hypertension and related conditions such as chronic kidney disease and obstructive sleep apnea. The company operates in the United States and relies on third-party manufacturers and clinical research organizations.
Based on the company's 10-K filed Mar 12, 2026.
Nasdaq · Healthcare
Mineralys Therapeutics, Inc. (MLYS)
What Is the Price Target for MLYS?
SEPT Low Target
$36.12
SEPT Mid Target
$42.50
SEPT High Target
$48.87
Analyst Consensus
$42.50
Is MLYS a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for MLYS.
Start Free Trial →Is MLYS Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$35.99
17
Moat Score
NONE
3/9
Piotroski Score
56.4
Altman Z-Score
What Is Smart Money Doing with MLYS?
Insider Signal
SELLING
0 buys / 10 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
DISTRIBUTING
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Peterson Kristine | director | Buy | 12,400 | - | Oct 19, 2026 |
| COATS LONNEL | director | Buy | 12,400 | - | Oct 19, 2026 |
| Congleton Jon | director officer | Sale | 75,000 | $1.9M | Sep 30, 2026 |
| Slingsby Brian Taylor | director | Sale | 104,320 | $3.0M | Sep 22, 2026 |
| Warren Eric | officer | Buy | 7,438 | $98K | Sep 21, 2026 |
| Warren Eric | officer | Sale | 7,438 | $209K | Sep 21, 2026 |
| Karydas Daphne | director | Buy | 3,000 | $36K | Sep 15, 2026 |
| Karydas Daphne | director | Sale | 3,000 | $86K | Sep 15, 2026 |
| Rodman David Malcom | officer | Buy | 6,349 | $7K | Jun 12, 2026 |
| Rodman David Malcom | officer | Sale | 6,349 | $152K | Jun 12, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →MLYS Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
37.43%
FCF Growth YoY
14.4%
Revenue Trend
UNKNOWN
Dark Pool Trades for MLYS
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for MLYS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:09 | $15.50 | 3,123 | $$48K | SELL |
| 21:00:09 | $15.50 | 2,800 | $$43K | SELL |
| 21:00:09 | $15.50 | 1,260 | $$20K | SELL |
| 21:00:08 | $15.50 | 1,431 | $$22K | SELL |
| 20:59:57 | $15.50 | 1,629 | $$25K | MIDPOINT |
5 dark pool trades shown · $$159K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for MLYS
PREVIEWSEPT Investing provides real-time options flow tracking for MLYS, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $17.5 | Mar 19 | 127 | $$429.6K | 999 | BLOCK |
| CALL | $17.5 | Mar 19 | 127 | $$368.5K | 996 | BLOCK |
| CALL | $17.5 | Mar 19 | 127 | $$148.0K | 400 | BLOCK |
3 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
What Traders Are Saying About MLYS
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for MLYS. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Zone Setup -- $MLYS (Mineralys Therapeutics, Inc.) Price: $23.98 | Zone: $22.30 to $26.78 Conviction: HIGH Near resistance (37% of range) — breakout watch. Strong positive news (1+ vs 0-)
Join 3,500+ traders discussing MLYS in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Mineralys Therapeutics, Inc. (MLYS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →MLYS — frequently asked questions
What is MLYS stock price today?
Mineralys Therapeutics, Inc. (MLYS) is at $15.50, down 4.08% (-$0.66) at the Nov 12, 2026 close.
Why is MLYS stock moving today?
Latest MLYS news — Nov 8, 2026: Mineralys Therapeutics reports late-breaking lorundrostat data from Transform-HTN extension · Nov 6, 2026: UBS trims its valuation view for Mineralys Therapeutics to $19
What is the MLYS price target?
The average analyst price target for MLYS is $42.50, ranging from $29 to $56, based on 2 analysts.
What do analysts rate MLYS?
Analyst ratings for MLYS: 0 Buy, 3 Hold, 0 Sell — consensus Hold.
Did MLYS beat earnings?
MLYS last reported on Aug 11, 2026: EPS -$2.85 vs -$0.55 expected — a miss of 419.5%.
Does MLYS pay a dividend?
MLYS does not currently pay a dividend.
How much debt does MLYS have?
Mineralys Therapeutics, Inc. reported $0M of debt and $138M of cash (Jun 30, 2026).
What are MLYS support and resistance levels?
Support: $15.33, $12.59, $10.44. Resistance: $17.66, $20.18, $22.48.
What are insiders doing with MLYS?
Insider activity: SELLING, 0 buys and 10 sells in the last 90 days.
What is the latest news on MLYS?
Nov 8, 2026: Mineralys Therapeutics reports late-breaking lorundrostat data from Transform-HTN extension · Nov 6, 2026: UBS trims its valuation view for Mineralys Therapeutics to $19 · Nov 4, 2026: Mineralys Therapeutics Posts Q3 2026 Financial Results